



NDA 20-571/S-026

Pfizer, Inc.  
Attention: Kristina D. Spranger, Director  
U.S. Regulatory Affairs  
235 East 42<sup>nd</sup> Street  
New York, NY 10017-5755

Dear Ms. Spranger:

Please refer to your supplemental new drug application dated March 30, 2005, received April 1, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for CAMPTOSAR® (irinotecan hydrochloride injection), 20 mg/mL.

This supplemental new drug application provides for information regarding the metabolism of CAMPTOSAR® by a polymorphic enzyme, uridinediphosphate glucuronosyl transferase 1A1 (UGT1A1) and its impact on drug dosing in specific populations. The incorporation of this information required labeling revisions to the **CLINICAL PHARMACOLOGY** section, **Pharmacokinetics, Metabolism and Excretion** subsection; the addition of a new subsection, **Patients with Reduced UGT1A1 Activity** to the **WARNINGS** section, and the addition of a new paragraph in the **DOSAGE AND ADMINISTRATION** section.

We have completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the package insert.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-571/S-026.**" Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Brenda Atkins, Regulatory Project Manager, at (301) 594-5767.

Sincerely,

*{See appended electronic signature page}*

Richard Pazdur, M.D.  
Director  
Division of Oncology Drug Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

Enclosure - Labeling

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Richard Pazdur  
6/7/05 03:31:49 PM